VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
30.4.2021 08:00:00 EEST | Business Wire | Press release
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro® (PA21) compared to sevelamer carbonate in lowering and maintaining serum phosphorus in adult Chinese patients with chronic kidney disease (CKD) on dialysis after 12 weeks of treatment. The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.
Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma Group commented, “We are delighted by the positive results from the PA-CL-CHINA-01 study, which confirm previous data generated in the US and Europe, and reinforce the potential of Velphoro® as an important new treatment option for dialysis patients with hyperphosphatemia in China where there is a high prevalence of CKD1. This is another important step in our geographic expansion and will further strengthen the position of Velphoro® as a global leader in the calcium-free phosphate binder market2.”
Importantly, patients who received Velphoro® experienced additional benefits compared to those in the sevelamer control group: Serum phosphorus levels in patients treated with Velphoro® declined faster than in the sevelamer group and the average number of tablets taken daily (3.23) was significantly lower than with sevelamer carbonate (6.31). Safety results were consistent with the known safety profile of Velphoro® with no new safety signal observed in Chinese CKD patients with hyperphosphataemia.
VFMCRP intends to submit the Chinese New Drug Application to the National Medical Products Administration’s CDE at the end of 2021.
About the PA-CL-CHINA-01 study
This phase-III study was designed to demonstrate non-inferiority of the change from baseline at week 12 in serum phosphorus between PA21 (Velphoro®) and sevelamer carbonate, and support market expansion of Velphoro® to China. PA-CL-CHINA-01 was an open-label, active-controlled, parallel group, multicenter study with a total of 286 patients randomized: 142 in the Velphoro® arm and 144 in the sevelamer arm. No major protocol deviation related to COVID-19 were reported and no patients were excluded from the Per Protocol Set (PPS) due to COVID-19.
About Velphoro®
Velphoro® is a non-calcium, iron-based, chewable phosphate binder approved for the control of phosphate levels in the blood of adults with CKD on dialysis. Velphoro® has been launched in over 30 countries, with more than 100,000 patients estimated to use the drug on a yearly basis. In 2020, Velphoro® became a global leader by value in the calcium-free phosphate binder market2.
References:
1 Zhang et al. Lancet. 2012 Mar 3;379(9818):815-22; Guo et al. Int J Environ Res Public Health 2016; 13: E770; Guo et al. Curr Cardiol Rev. 2013 May; 9(2): 112–122.
2 Monthly IQVIA MIDAS panel, INSIGHT Health & DN, GERS, DLI, Farminform | 03.2020.
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005950/en/
Contact information
Media Relations
Nathalie Ponnier
Global Head Corporate Communications
+41 79 957 96 73
media@viforpharma.com
Investor Relations
Julien Vignot
Head of Investor Relations
+41 58 851 66 90
investors@viforpharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Establishes New Member Firm in France8.9.2026 16:30:00 EEST | Press release
Andersen Global adds depth to its presence in France with the addition of Andersen Société d'Avocats (Andersen in France), a Paris-based member firm offering integrated legal capabilities to clients in France and internationally. Andersen in France provides strategic legal solutions on matters involving corporate tax, international tax, transfer pricing, VAT, and tax litigation, supporting clients around the world. Under the leadership of managing partners Benoît Dambre and François Morazin, the multidisciplinary team also handles specialized matters involving urban planning, real estate, intellectual property and privacy, sustainability and ESG, EU law and sanctions, and other complex legal issues. “We see legal advice as more than addressing immediate challenges; it should help clients make informed decisions and pursue opportunities with confidence,” said Benoît. “Becoming a member firm of Andersen Global allows us to combine that client-focused approach with broader international c
AI Can Design the Slides, But It Can’t Fix Stage Fright: 3 in 4 Workers Get Anxious Presenting, Canva Study Finds8.9.2026 16:00:00 EEST | Press release
New research from Canva, the world’s leading visual communication platform, reveals an emerging paradox at the heart of one of work’s age-old skills: even as AI makes presentations easier to create than ever, nearly three in four professionals (74%) still feel anxious about presenting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908549712/en/ Canva's Global 'The Presentation Paradox' Study Few things are as entrenched as presentations, and decade after decade, they’ve defined how we communicate to clients, teammates, leadership, and beyond. Now, AI is changing them by making them faster and easier to create than ever. Nine in 10 (91%) workers use AI monthly to build slides, mainly for design (57%), brainstorming (56%) and drafting content (49%). 48% say it saves them more than an hour per presentation. As AI use grows, more than 100 million people create presentations on Canva every month, and it is one of the top use
PAX Debuts The Oxblood Edit, a Limited Edition Collection Inspired by Fall’s Richest Color8.9.2026 16:00:00 EEST | Press release
Today PAX, a pioneering global cannabis brand, introduces The Oxblood Edit, an ultra-limited release bringing one of fall’s defining colors to three of the brand’s signature devices: PAX FOUR, PAX MINI and ERA GO. Deep, distinctive and designed to be coveted, Oxblood transforms the PAX lineup through a rich burgundy finish inspired by the worlds of fashion, interiors and industrial design. The limited collection is available beginning today at pax.com and select retailers, while supplies last. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908330141/en/ The Oxblood Edit: bringing timeless style, seasonal color, and elevated design to three of the brand's signature devices. Long associated with craftsmanship and enduring style, oxblood has reemerged across fashion, footwear, accessories and interiors as consumers gravitate toward richer palettes, timeless materials and elevated essentials. For PAX, the color is less about
STARTEEPO Issues Letter and Presentation to the Board of Xerox Calling for Action to Unlock Shareholder Value8.9.2026 16:00:00 EEST | Press release
STARTEEPO SICAV a.s. (“STARTEEPO”) today issued an investor presentation and the following letter to the Board of Directors (the “Board”) of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX). STARTEEPO, which has increased its investment in Xerox to a beneficial ownership of 7.34%, in stocks and options, is urging the Board to take bold actions to unlock significant shareholder value, including by increasing transparency about Xerox Financial Services’ performance, evaluating strategic alternatives for the business unit, deleveraging the Company, and exercising continued capital discipline. Shareholders can view the investor presentation here. For more information visit: www.starteepo.com/xerox. The full text of the letter follows: September 7, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Since we first wrote to you in May, we have increased our already significant investment in Xerox Holdings Corp. to a b
Leblon Delienne Joins LEXON at BOW to Expand Its Global Reach8.9.2026 15:36:00 EEST | Press release
BOW (Brands of Wonder), the international brand group behind French design brand LEXON, today announced the acquisition of Leblon Delienne, the French sculpture atelier known for transforming pop culture icons into collectible art and design objects. The move pairs the atelier’s distinctive French craftsmanship and licensed collections with BOW’s international reach and digital expertise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908641342/en/ Leblon Delienne Joins LEXON at BOW Juliette de Blegiers, who acquired the company in 2018, will remain a minority shareholder in Leblon Delienne and continue working alongside BOW founder Boris Brault and the atelier’s teams. For more than 40 years, Leblon Delienne has brought iconic characters to life through sculptures, figurines, furniture, and art and design objects, primarily in limited, numbered editions. Its licensed collections feature characters from Disney, Warner Bro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom